Publications

CTD² scientists developed an Onco-GPS tool—a data-driven approach useful in establishing relationships—to explore cancers with altered RAS/MAPK. These components help to map individual samples onto a novel visual paradigm and strategize therapy against cancers with well-defined oncogenic lesions.

Scientists have developed a cancer dependency map by combining off-target effects of RNAi and genomic characterization information across 501 cancer cell lines. The map facilitates identification and prioritization of therapeutic targets by predicting the genes essential for cell viability.

Plasticity of the cell state is proposed to drive resistance to multiple classes of cancer therapies. CTD2 researchers characterized this therapy-resistant cell state in human cancer cells and identify vulnerability to ferroptosis by inhibition of a lipid peroxidase.